Jane Street Group, LLC Outlook Therapeutics, Inc. Transaction History

Jane Street Group, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.22 - $0.66 $11,634 - $34,902	52,883 New	52,883 $20,000
Q2 2023 Aug 14, 2023	BUY	$1.02 - $1.89 $24,111 - $44,677	23,639 New	23,639 $41,000
Q4 2022 Feb 14, 2023	BUY	$0.87 - $1.33 $6,271 - $9,587	7,209 Added 68.26%	17,770 $19,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.26 $10,772 - $13,306	10,561 New	10,561 $13,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.26 $10,772 - $13,306	10,561 New	10,561 $13,000
Q2 2022 Aug 16, 2022	SELL	$0.91 - $2.01 $74,195 - $163,881	-81,533 Closed	0 $0
Q1 2022 May 17, 2022	BUY	$1.22 - $2.03 $99,470 - $165,511	81,533 New	81,533 $145,000
Q3 2021 Nov 16, 2021	SELL	$2.12 - $2.76 $135,610 - $176,548	-63,967 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$1.78 - $2.76 $113,861 - $176,548	63,967 New	63,967 $160,000
Q4 2019 Feb 14, 2020	SELL	$0.53 - $1.59 $9,420 - $28,260	-17,774 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$1.32 - $2.63 $23,461 - $46,745	17,774 New	17,774 $26,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.